Trial Profile
A Phase II Study of Palbociclib Plus Fulvestrant for Pretreated Patients With ER+/HER2- Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PYTHIA
- 30 Mar 2023 This trial has been completed in Belgium (End Date: 22 Dec 2022), according to European Clinical Trials Database record.
- 13 Feb 2022 Primary endpoint (Progression Free Survival (PFS) has been met according to the results published in the European Journal of Cancer
- 13 Feb 2022 Results published in the European Journal of Cancer